On November 27, 2025, President Donald Trump announced that the United States would initiate land-based operations against suspected drug trafficking networks in Venezuela “very soon.” This escalation follows a series of maritime strikes in the Caribbean, which the administration claims have intercepted 85% of sea-borne drug shipments originating from the region. The move builds on earlier actions, including the authorization of CIA covert operations and the designation of Venezuela’s alleged “Cartel de los Soles”—a network purportedly embedded in the military—as a terrorist organization. Secretary of War Pete Hegseth has indicated that this status could unlock additional tools, such as targeted strikes on drug facilities. While aimed at curbing the flow of narcotics into the U.S., these plans raise broader questions about the roots of America’s drug challenges and the consistency of its foreign policy responses.
To understand the context, it is essential to revisit the origins of the opioid crisis that these efforts ostensibly address. Contrary to narratives emphasizing foreign suppliers, the epidemic’s foundations lie firmly within the United States, driven by aggressive marketing and regulatory lapses in the pharmaceutical sector. Purdue Pharma, owned by the Sackler family, played a pivotal role through its promotion of OxyContin, approved by the FDA in 1995 as a less addictive alternative for chronic pain management. Internal documents later revealed that the company downplayed addiction risks, funding studies that misrepresented the drug’s safety profile and paying doctors incentives—often disguised as educational grants—to prescribe it liberally.
The scale of the impact is staggering. From 1999 to 2019, prescription opioid overdoses claimed approximately 247,000 lives in the U.S., according to Supreme Court records in a 2024 case involving Purdue. By 2018, the Sackler family had withdrawn over $10 billion from the company amid rising overdose deaths, which peaked at more than 130 per day in states like Michigan, where “pill mills” proliferated. Regulatory scrutiny culminated in a 2020 Justice Department settlement where Purdue pleaded guilty to felony charges, agreeing to pay $8.3 billion, while the Sacklers contributed $225 million in civil damages. More recently, in January 2025, a multistate agreement secured an additional $7.4 billion from Purdue and the family to fund addiction treatment and prevention programs. These developments underscore a systemic failure: the FDA’s expedited approval process and the influence of industry lobbying allowed opioids to flood communities, creating a domestic supply chain that predated and exacerbated illicit imports.
This internal dynamic complicates the framing of Venezuela as a primary culprit. U.S. intelligence estimates suggest that only about 8% of cocaine bound for the U.S. transits Venezuelan waters, with major routes shifting to Central America and Mexico in recent years. Moreover, historical U.S. involvement in Latin American drug networks adds layers of irony to current interventions. Declassified documents from the 1980s Iran-Contra affair reveal that the CIA tolerated and, in some instances, facilitated cocaine trafficking by Nicaraguan Contra rebels to fund their anti-Sandinista operations. A 1996 series by journalist Gary Webb in the San Jose Mercury News—later compiled in his book Dark Alliance—detailed how Bay Area drug rings, protected by CIA assets, funneled millions from crack cocaine sales in Los Angeles to the Contras, contributing to the urban crack epidemic.
Official investigations, including a 1998 CIA Inspector General report, acknowledged that agency officers had contacts with known traffickers but denied direct complicity. Nonetheless, the National Security Archive’s declassified files show U.S. officials intervening to prevent the deportation of Contra-linked drug suspects and collaborating with figures like Panamanian dictator Manuel Noriega, who facilitated shipments before his 1989 ouster. In Colombia and Mexico, similar patterns emerged during the 1990s and 2000s, where CIA-backed anti-narcotics efforts sometimes aligned with cartel factions to counter leftist insurgencies. These precedents highlight how U.S. foreign policy priorities—such as Cold War containment—have inadvertently sustained the very networks now targeted, raising questions about the efficacy of unilateral actions like those proposed for Venezuela.
Against this backdrop, Trump’s Venezuela strategy appears selectively focused. While maritime interdictions have yielded results, land operations risk entangling U.S. forces in Venezuela’s complex terrain and politics, where economic sanctions have already deepened poverty and migration pressures. President Nicolás Maduro has vowed to defend “every inch” of the country, potentially drawing in allies like Russia and China, who have expanded military and economic ties with Caracas. This could echo past U.S. interventions, such as the 1989 Panama invasion, which disrupted one regime but failed to stem regional drug flows.
Compounding these concerns is the timing of the announcement, coming just days after Trump signed legislation on November 19, 2025, mandating the Justice Department to release Jeffrey Epstein’s files within 30 days. The bipartisan bill, passed overwhelmingly despite initial Republican resistance, includes searchable formats for the documents, which encompass flight logs, victim statements, and communications implicating high-profile figures. Trump’s name appears in preliminary disclosures, including emails from a November 12 House Oversight Committee release, prompting speculation about his earlier opposition—Attorney General Pam Bondi reportedly informed him in May 2025 of his mentions. The president has touted the signing as a transparency victory, yet the law contains exceptions for national security redactions, allowing selective withholding.
Critics, including Democrats and some Republicans, argue this external focus diverts attention from domestic accountability, much like how opioid settlements have prioritized payouts over structural reforms. The Epstein files, long delayed despite public demands, could illuminate elite networks that parallel the very corruption Trump vows to combat abroad. As the U.S. contemplates boots on Venezuelan soil, a more effective path might involve bolstering internal efforts: expanding FDA oversight, funding community-based treatment (as in the $7.4 billion Purdue accord), and declassifying historical records to inform future policy.
Ultimately, addressing drug challenges requires confronting root causes at home and abroad, rather than isolated military campaigns. With over 80 deaths already linked to recent Caribbean strikes and broader regional tensions rising, policymakers must weigh whether escalation serves U.S. interests or perpetuates cycles of intervention and unintended consequences. A fact-driven reassessment could foster sustainable solutions, benefiting communities on both sides of the border.
